Listened to the presentation | NBIX Message Board Posts

Neurocrine Biosciences, Inc.

  NBIX website

NBIX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  47715 of 47768  at  3/2/2021 2:13:13 PM  by

goirish1776


Listened to the presentation

Missed the first two minutes.  Doubt I missed much.
 
- Announcement today.  Look under hood to see if impact on cognition is real.  If so, it's a big deal (80%+ patients have cognition issues).  Long way out, I assume, unless they'll take the data and roll into a PIII.  He said PII, so I don't expect much.
 
- Ingrezza -- standard line.  Q1 tough.  Early innings.
 
- Opicapone -- "as expected", which is to say, slow.  Sounds like payment is complicated (hoops) and no fun.  Still, long-term hopeful.
 
- Huntington's (PIII) -- readout in Q4.  Benefits over the competition.  [Are the problems with current drugs really hindering adoption?] 
 
- CAH (PIII Adults) -- Update later this year on the timing of data readout.  
 
- Epilepsy drug/CAH for children (PII) -- Blah, blah, blah.
 
Where's the next "blockbuster"?  A long way away.
 
The best thing they have going for them in the next six to nine months is Ingrezza. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
47716 Re: Listened to the presentation coldpizza 1 3/2/2021 3:41:46 PM
47725 Re: Listened to the presentation bier4me 0 3/8/2021 11:06:25 AM








Financial Market Data provided by
.
Loading...